Gynostemma Pentaphyllum for Dyslipidemia: A Protocol of Systematic Review of Randomized Controlled Trials

Ning Dai,Fang-Fang Zhao,Min Fang,Feng-Lan Pu,Ling-Yao Kong,Jian-Ping Liu
DOI: https://doi.org/10.37766/inplasy2022.1.0135
2022-01-01
Abstract:Review question / Objective: The aim of this systematic review is to compare Chinese herb Gynostemma pentaphyllum with no treatment, placebo, lipid-lowering agents, or other Chinese herbal products that containing red yeast rice extracts to evaluate effectiveness, safety and cost-effectiveness in people with dyslipidemia to inform clinical practice. To this end, the proposed systematic review will address the following question: Is Chinese herb Gynostemma pentaphyllum effective for dyslipidemia? Information sources: The PubMed, the Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), SinoMed, and Wanfang Data will be searched in January 2022. We also explored the World Health Organization International Clinical Trials Registry Platform (https://www.who.int/clinical-trials-registry-platform), ClinicalTrials.gov (www.clinicaltrials.gov/), and the Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx) for ongoing or unpublished trials to January 2022. Subject words or text words are determined based on published systematic reviews, clinical practice guidelines, ICD-10, ICD-11, MeSH terms, and Emtree. In addition, the reference lists of all identified studies will also be searched to find any relevant trials for inclusion.
What problem does this paper attempt to address?